Premium
P4‐228: Pharmacological aspects related to the management of behavioral symptoms in elderly patients with ALZHEIMER'S disease: A review
Author(s) -
Rocha Juliana,
Piovezan Ronaldo,
Cendoroglo Maysa Seabra
Publication year - 2012
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2012.05.1933
Subject(s) - medicine , disease , memantine , dementia , quality of life (healthcare) , population , psychological intervention , intensive care medicine , psychiatry , nursing , environmental health
Alzheimer’s disease, however, whether CD treatment prevents neuronal loss, plaque burden and tau pathology in AD is still largely unexplored. Methods: In vitro: cultured sw-N2a cells and N2a cells. In vivo: Tg19959 and littermates. Biochemical, histological methods, fluorescence immunostaining and behavioral tests were used. Results: We observed the elevated membrane cholesterol level in N2a cells overexpressing Swedish mutant APP (SwN2a). Cholesterol accumulation can be also seen at the plaques in 4 month old Tg19959 mice brain. Then we treated SwN2a cells with CD, it reduced membrane cholesterol level, reduced Ab 42 levels dramatically and also improved mitochondrial oxygen consumption in vitro. Tg19959 mice treated with CD showed not only reduced Ab plaques but also reduced pathological tau immunoreactive to AT8. In addition, CD treatment also improved spatial learning and memory in Tg19959 mice. Conclusions: Taken together, our results show the neuroprotection of cyclodextrin and indicate the promising direction of using non-toxic compound cyclodextrin to treat Alzheimer’s disease.